These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30358871)

  • 1. GI Dysfunctions in Diabetic Gastroenteropathy, Their Relationships With Symptoms, and Effects of a GLP-1 Antagonist.
    Chakraborty S; Halland M; Burton D; Desai A; Neja B; Low P; Singer W; Camilleri M; Zinsmeister AR; Bharucha AE
    J Clin Endocrinol Metab; 2019 Jun; 104(6):1967-1977. PubMed ID: 30358871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between symptoms during a gastric emptying study and intestinal chemosensitivity with daily symptoms.
    Chakraborty S; Desai A; Halland M; Burton D; Camilleri M; Zinsmeister AR; Bharucha AE
    Neurogastroenterol Motil; 2019 Oct; 31(10):e13686. PubMed ID: 31328363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed Gastric Emptying Is Associated With Early and Long-term Hyperglycemia in Type 1 Diabetes Mellitus.
    Bharucha AE; Batey-Schaefer B; Cleary PA; Murray JA; Cowie C; Lorenzi G; Driscoll M; Harth J; Larkin M; Christofi M; Bayless M; Wimmergren N; Herman W; Whitehouse F; Jones K; Kruger D; Martin C; Ziegler G; Zinsmeister AR; Nathan DM;
    Gastroenterology; 2015 Aug; 149(2):330-9. PubMed ID: 25980755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and predictors of delayed gastric emptying among Indian patients with long-standing type 2 diabetes mellitus.
    Anudeep V; Vinod KV; Pandit N; Sharma VK; Dhanapathi H; Dutta TK; Sujiv A
    Indian J Gastroenterol; 2016 Sep; 35(5):385-392. PubMed ID: 27667549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study.
    Camilleri M; McCallum RW; Tack J; Spence SC; Gottesdiener K; Fiedorek FT
    Gastroenterology; 2017 Nov; 153(5):1240-1250.e2. PubMed ID: 28760384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastric Emptying Impacts the Timing of Meal Glucose Peak in Subjects With Uncomplicated Type 1 Diabetes.
    Lupoli R; Creanza A; Griffo E; Nardone G; Rocco A; Bozzetto L; Annuzzi G; Riccardi G; Capaldo B
    J Clin Endocrinol Metab; 2018 Jun; 103(6):2269-2276. PubMed ID: 29659867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between allelic variants in the glucagon-like peptide 1 and cholecystokinin receptor genes with gastric emptying and glucose tolerance.
    Anderson B; Carlson P; Laurenti M; Vella A; Camilleri M; Desai A; Feuerhak K; Bharucha AE
    Neurogastroenterol Motil; 2020 Jan; 32(1):e13724. PubMed ID: 31691451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationships of Glucose, GLP-1, and Insulin Secretion With Gastric Emptying After a 75-g Glucose Load in Type 2 Diabetes.
    Jalleh RJ; Wu T; Jones KL; Rayner CK; Horowitz M; Marathe CS
    J Clin Endocrinol Metab; 2022 Aug; 107(9):e3850-e3856. PubMed ID: 35608823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function.
    Kielgast U; Holst JJ; Madsbad S
    Diabetes; 2011 May; 60(5):1599-607. PubMed ID: 21441444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small intestinal bacterial overgrowth in diabetic gastroenteropathy.
    Varma R; Chakraborty S; Burton DD; Bailey KR; Bharucha AE
    Neurogastroenterol Motil; 2024 Jul; 36(7):e14798. PubMed ID: 38651669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses.
    Little TJ; Pilichiewicz AN; Russo A; Phillips L; Jones KL; Nauck MA; Wishart J; Horowitz M; Feinle-Bisset C
    J Clin Endocrinol Metab; 2006 May; 91(5):1916-23. PubMed ID: 16492694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus.
    Shin A; Camilleri M; Busciglio I; Burton D; Smith SA; Vella A; Ryks M; Rhoten D; Zinsmeister AR
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1453-1459.e4. PubMed ID: 23639598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial.
    Thazhath SS; Wu T; Bound MJ; Checklin HL; Standfield S; Jones KL; Horowitz M; Rayner CK
    Am J Clin Nutr; 2016 Jan; 103(1):66-70. PubMed ID: 26607942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ondansetron on symptoms during a gastric emptying study and enteral lipid challenge and on daily symptoms in diabetic gastroenteropathy.
    Varma R; Chakraborty SC; Ramu SK; Burton DD; Deb B; Ryks MD; Feuerhak KJ; Bailey KR; Bharucha AE
    Neurogastroenterol Motil; 2024 Jun; ():e14857. PubMed ID: 38946172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo-controlled, double-blind, parallel-group study.
    Frandsen CS; Dejgaard TF; Andersen HU; Holst JJ; Hartmann B; Thorsteinsson B; Madsbad S
    Diabetes Obes Metab; 2017 Jun; 19(6):773-782. PubMed ID: 27868372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed Gastric Emptying Associates With Diabetic Complications in Diabetic Patients With Symptoms of Gastroparesis.
    Parkman HP; Wilson LA; Farrugia G; Koch KL; Hasler WL; Nguyen LA; Abell TL; Snape W; Clarke J; Kuo B; McCallum RW; Sarosiek I; Grover M; Miriel L; Tonascia J; Hamilton FA; Pasricha PJ;
    Am J Gastroenterol; 2019 Nov; 114(11):1778-1794. PubMed ID: 31658129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of exogenous glucagon-like peptide-1 on blood pressure, heart rate, gastric emptying, mesenteric blood flow and glycaemic responses to oral glucose in older individuals with normal glucose tolerance or type 2 diabetes.
    Trahair LG; Horowitz M; Stevens JE; Feinle-Bisset C; Standfield S; Piscitelli D; Rayner CK; Deane AM; Jones KL
    Diabetologia; 2015 Aug; 58(8):1769-78. PubMed ID: 26048234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade.
    Aulinger BA; Bedorf A; Kutscherauer G; de Heer J; Holst JJ; Göke B; Schirra J
    Diabetes; 2014 Mar; 63(3):1079-92. PubMed ID: 24296715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between symptoms during a gastric emptying study, daily symptoms and quality of life in patients with diabetes mellitus.
    Kuwelker S; Prichard DO; Bailey K; Bharucha AE
    Neurogastroenterol Motil; 2021 Dec; 33(12):e14154. PubMed ID: 33830588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effects of proximal and distal small intestinal administration of metformin on plasma glucose and glucagon-like peptide-1, and gastric emptying after oral glucose, in type 2 diabetes.
    Borg MJ; Bound M; Grivell J; Sun Z; Jones KL; Horowitz M; Rayner CK; Wu T
    Diabetes Obes Metab; 2019 Mar; 21(3):640-647. PubMed ID: 30370686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.